Investigational anti-CNDN18.2 ADCs for the treatment of G/GEJAC patients and anti-CLDN6 and anti-CDH6 ADCs for the treatment of ovarian cancer have also proceeded to later-stage clinical trials. The gene discussed is CLDN6; the disease is ovarian cancer.